CHOSEN raises $5M Series A to scale clinic-led, science-driven skincare for melanin-rich skin

Table of Contents

1. Key Highlights
2. Introduction
3. Why melanin-rich skin needs tailored science
4. How CHOSEN built a clinic-to-consumer model and why it matters
5. What the Series A funding enables: R&D, talent and a Centre of Excellence
6. The strategic value of investors: why L’Oréal’s BOLD and Fireside matter
7. Product portfolio and formulation priorities for skin of color
8. Expansion beyond India: opportunities and regulatory realities
9. Competitive landscape: legacy dermatology brands vs. clinic-led challengers
10. Operational and commercial challenges ahead
11. Practical roadmap: how CHOSEN can deploy capital and scale responsibly
12. Real-world parallels and lessons from other clinical-first brands
13. Risks to watch and mitigation strategies
14. The broader market implication: specialization and clinical trust as currency
15. FAQ

Key Highlights

• CHOSEN secured $5 million in a Series A round led by Fireside Ventures, with participation from L’Oréal’s corporate VC fund BOLD, Alkemi Growth Capital and several angel investors; the company previously raised $1.2 million in 2024.
• The capital will accelerate R&D, expand a clinically validated product pipeline across topicals and nutraceuticals, scale its Centre of Excellence and recruit talent to support expansion into global “skin of color” markets.
• CHOSEN operates a clinic-to-consumer model built on 150,000+ consultations, sells roughly 58 SKUs across doctor-led and D2C channels, is prescribed in over 2,000 clinics nationwide, and reports ~70% revenue from repeat customers (primarily women aged 30–50).

Introduction

A new chapter in India’s specialized skincare market is underway. CHOSEN, a Chennai-founded brand that designs dermatology-led formulations for melanin-rich skin, has closed a $5 million Series A round. Investors include Fireside Ventures and BOLD, the corporate venture arm of L’Oréal—an alignment that signals strategic value beyond capital alone. The funding arrives at a moment when consumer demand for evidence-backed, targeted solutions for pigmentary concerns and age-related changes among darker skin types is accelerating. CHOSEN’s clinic-to-consumer approach, a portfolio spanning topical therapeutics and nutraceuticals, and a claims-backed research emphasis position it to challenge both legacy dermatological brands and fast-growing D2C incumbents.

The round will deepen CHOSEN’s research infrastructure, broaden clinical validation, scale operations and support international entry into Latin America and East Asia—regions with comparable dermatological needs. What follows is an examination of CHOSEN’s model, the science behind addressing melanin-rich skin, the significance of its investors, the competitive landscape, and the practical hurdles and strategic moves that will determine whether the brand can convert clinical credibility into sustained global growth.

Why melanin-rich skin needs tailored science

Skin pigmentation affects not just appearance but biology: barrier function, inflammatory responses and how skin ages can differ across phototypes. These differences make one-size-fits-all formulations and protocols inadequate. For melanin-rich skin, persistent hyperpigmentation and post-inflammatory hyperpigmentation (PIH) are major patient concerns. The treatments that work best blend actives that modulate melanin synthesis, accelerate controlled cellular turnover, reduce inflammation and protect against external triggers.

CHOSEN frames its work around the exposome—the cumulative external and internal exposures that drive skin aging and pigmentation changes. That scientific framing steers product development toward multifactorial interventions: sunscreens for UV-mediated melanogenesis, antioxidants for oxidative stress, anti-inflammatory actives to blunt PIH, and modulators of melanogenesis such as niacinamide, azelaic and tranexamic acids, and stabilized vitamin C derivatives. Nutraceuticals are added to support skin health from the inside, addressing systemic contributors like oxidative load and collagen integrity.

A clinical mindset matters because some high-efficacy actives that work on lighter skin carry a higher risk of irritation or paradoxical pigmentation when used improperly on melanin-rich skin. Dermatologist supervision reduces this risk by personalizing concentrations and combinations, sequencing retinoids or acids with calming and barrier-supporting ingredients, and ensuring photoprotection is emphasized. CHOSEN’s clinic-to-consumer pathway attempts to capture that nuance—patients start treatment under a clinician’s guidance and continue maintenance through the brand’s D2C platform.

How CHOSEN built a clinic-to-consumer model and why it matters

CHOSEN launched in 2020 under Renita Rajan with a mission to translate dermatology protocols into consumer-appropriate regimens for Indian skin. The company has collected data from more than 150,000 consultations, and it leverages a B2B network of dermatologists who prescribe its products in over 2,000 clinics. That reach establishes clinical trust and creates a prescription-to-maintenance pipeline: clinics initiate treatment with targeted regimens and patients transition to e-commerce for follow-up and long-term maintenance.

This hybrid model offers several advantages:

• Clinical validation and endorsement accelerate consumer trust. Dermatologist prescriptions signal efficacy and safety, which is crucial in categories where results and side effects matter.
• Higher customer lifetime value. The brand reports roughly 70% of revenue coming from repeat buyers, particularly women aged 30–50—an age group that is motivated to invest in clinically effective solutions for pigmentation and texture.
• Controlled conversion funnel. Clinician engagement creates a funnel for higher-acuity customers who are primed to adopt evidence-based routines and maintain compliance.
• Data feedback loop. Practitioner prescriptions and follow-up consultations create rich, real-world evidence that can refine formulations and support claims for future products.

Other brands have followed pieces of this pathway—pharmacy-led dermatology brands, aesthetic clinics launching product lines, and D2C companies partnering with dermatologists for credibility. CHOSEN’s integration at scale—thousands of clinics paired with an owned digital platform accounting for nearly 95% of its online sales—combines clinician validation with D2C economics.

What the Series A funding enables: R&D, talent and a Centre of Excellence

CHOSEN will allocate capital toward strengthening research and development, expanding a pipeline of clinically validated products, scaling its Centre of Excellence and hiring high-impact talent across functions. Those investments map directly to recurring constraints facing clinically oriented skincare startups.

R&D and clinical validation Clinical studies are expensive and time-consuming but indispensable for claims that distinguish a brand in a crowded market. CHOSEN’s focus on evidence-based products suggests trials will center on efficacy endpoints relevant to melanin-rich skin: reduction in hyperpigmented lesions, prevention of PIH following procedures, improvement in skin texture and contour, and tolerability metrics. Randomized controlled trials, assessor-blinded evaluation and instrumental endpoints such as colorimetry and 3D imaging will strengthen product dossiers and provide dermatologists with reproducible outcomes to base prescriptions on.

Scaling a Centre of Excellence A dedicated Centre of Excellence can centralize protocol development, clinical partnerships, in-house testing, and training for dermatologist partners. It also becomes a hub for real-world evidence collection—standardizing consultation data, orchestrating post-marketing surveillance, and facilitating investigator-initiated studies. For a brand that sells both topicals and nutraceuticals, the centre can coordinate cross-disciplinary research, combining dermatology, nutrition, and cosmetic science.

Talent and operations Clinically credible brands require specialized hires: clinical researchers, regulatory experts, formulation chemists, medical affairs teams and regulatory affairs professionals who can manage multi-market product registrations. On the commercial side, scaling D2C operations means investing in digital marketing, retention programs, logistics and customer support tailored for patient follow-up rather than one-off cosmetic purchases.

The strategic value of investors: why L’Oréal’s BOLD and Fireside matter

The investor mix—led by Fireside Ventures with BOLD participating—offers capital and strategic resources. Fireside brings experience backing early-stage consumer brands in India and scale-up expertise across retail and digital distribution. BOLD’s presence as L’Oréal’s corporate venture fund signals potential access to technical knowledge, global distribution frameworks, and regulatory insights. Even if a corporate investor stops short of full acquisition, their involvement helps a brand navigate product safety standards, ingredient sourcing, manufacturing scale and global launch pathways.

Alkemi Growth Capital and angel participation provide additional capital and entrepreneur networks. Individual backers like Avnish Anand and other industry veterans bring operational perspectives on brand-building in consumer products and marketplace growth.

Collectively, these investors can accelerate CHOSEN’s product validation timelines, help de-risk international launches, and amplify credibility among dermatologists and retail partners.

Product portfolio and formulation priorities for skin of color

CHOSEN currently operates about 58 SKUs across doctor-led and D2C segments. Managing that breadth demands careful SKU rationalization so clinical clarity isn’t lost. For skin-of-color markets, formulation priorities include:

• Efficacy with gentleness: actives that reduce melanogenesis yet preserve barrier function and minimize irritation. Niacinamide (brightening and barrier-supporting), azelaic acid (anti-inflammatory and pigment modulator), tranexamic acid (vascular-related hyperpigmentation), and stabilized vitamin C (antioxidant and brightener) fit this profile.
• Photoprotection: broad-spectrum sunscreens with user-friendly textures and high compliance factors. For darker skin tones, formulations that avoid white cast and have cosmetically acceptable finishes are critical.
• Anti-inflammatory adjuncts: ingredients like centella asiatica, panthenol and ceramides to mitigate PIH risk, particularly when combining actives that increase cellular turnover.
• Deliverability and compliance: serum-plus-moisturizer regimens that simplify routines to combat low adherence. Nutraceuticals can complement topical regimens when evidence supports systemic benefits—antioxidants, collagen peptides and targeted micronutrients are common categories.
• Safety and claim substantiation: for markets with strict regulatory frameworks, claims must be backed with appropriate studies. This includes avoiding ambiguous language and ensuring labeling meets local rules on cosmeceutical claims.

Managing 58 SKUs while upgrading clinical validation requires prioritizing formulations that address the most prevalent unmet needs: pigment correction, PIH prevention, and texture/contour improvements.

Expansion beyond India: opportunities and regulatory realities

CHOSEN plans to expand into “skin of color” markets such as parts of Latin America and East Asia. These regions share overlapping dermatological concerns—prominent hyperpigmentation, sensitivity to irritation, and high consumer demand for brightening and anti-aging solutions. However, successful entry requires adaptation across multiple dimensions.

Regulatory pathways Cosmetic and cosmeceutical regulations vary by market. Ingredient approvals, permissible claims and safety testing requirements differ between India, Latin America and East Asia. Some markets require product registration with national agencies; others have notification systems. Dermatology-driven claims and active ingredient concentrations can face scrutiny. Regulatory expertise and local partnerships are essential to avoid costly reformulation or relabeling.

Cultural nuance and marketing Skin care perceptions vary. In parts of Latin America, “brightening” often conflates with whitening and has different cultural resonances. Messaging must be localized to emphasize healthy, even-toned skin rather than notions that can provoke backlash. In East Asia, fast adoption of high-efficacy innovations exists alongside strong demand for lightweight textures and layering systems. Packaging design, fragrance profiles and routine positioning should reflect regional preferences.

Distribution strategy Clinic networks are not uniform globally. CHOSEN’s clinic-centric model may translate well in markets where dermatologists are primary prescribers. In regions where pharmacies or beauty retailers dominate, alternative partnerships will be required. E-commerce, particularly owned D2C channels, can maintain margins and control over customer data, but marketplace presence and omnichannel partnerships may accelerate reach.

Local clinical partnerships Establishing relationships with local dermatologists and key opinion leaders will lend credibility and facilitate real-world studies in target populations. Investigator-led trials in local cohorts provide relevant data for regulatory submissions and clinician adoption.

Competitive landscape: legacy dermatology brands vs. clinic-led challengers

CHOSEN faces competition from established brands and newer clinical players. Competitors named in the source—Avène, Heliocare, Cetaphil, Sebamed, Shiseido and Dr. Sturm—span pharmacy and prestige segments.

How CHOSEN differentiates

• Skin-of-color focus. While many legacy brands position themselves as broadly effective, CHOSEN centers melanin-rich skin as the primary development target.
• Clinic-led validation. A network of over 2,000 clinics prescribing CHOSEN creates a clinician-first adoption path that many D2C brands lack.
• Evidence orientation. A pipeline built on clinical validation positions the brand for prescriber trust and durable consumer loyalty.

Competitive pressures

• Legacy brands have distribution breadth, manufacturing scale and marketing budgets that can rapidly neutralize niche entrants.
• Prestigious medical brands with surgeon or aesthetician networks may offer overlapping clinical credibility.
• D2C players that emphasize affordability and simplified regimens can win price-sensitive segments.

To sustain advantage, CHOSEN needs to protect clinical integrity while scaling cost-effectively and maintaining a tight feedback loop between clinicians and R&D.

Operational and commercial challenges ahead

Scaling from early traction to sustainable national and international operations exposes recurring risks.

Ingredient sourcing and manufacturing Maintaining formulation quality at scale requires reliable suppliers, validated manufacturing processes and quality systems. For clinically positioned products, batch-to-batch consistency, microbial testing and stability studies are non-negotiable. Sourcing actives at medical-grade concentrations may involve supply scarcity or price volatility.

Regulatory and labeling compliance As CHOSEN adds medical-grade claims or higher active percentages, regulatory categorization can shift, bringing registration and clinical trial demands. Global claims management will require localized safety data and translation of clinical endpoints into permissible marketing language.

Channel management and clinician relations Clinic partnerships must be nurtured to avoid channel conflict. Dermatologists expect scientific backing and fair channel incentives. If D2C promotions undercut clinic-prescribed prices or create perception issues, clinician partnerships may weaken. Aligning incentives and ensuring that clinical authority is preserved in communications will be essential.

Customer acquisition and retention economics Converting clinic patients into long-term D2C customers depends on seamless onboarding, regimen clarity and ongoing support. Older consumers—CHOSEN’s core buyers are women 30–50—value education and outcomes over trend-led purchases, making medical content and results-focused narratives effective. Still, customer acquisition costs in skincare escalate quickly in digital channels; optimizing retention and lifetime value is crucial for unit economics.

Intellectual property and claims protection Clinical evidence offers an advantage but is not a substitute for IP protection. Patents on unique formulations or delivery technologies can protect margins. Where ingredients and actives are standard, clinical datasets and brand trust become the moat.

Practical roadmap: how CHOSEN can deploy capital and scale responsibly

A pragmatic, staged approach will increase the odds of successful scale-up and international entry.

Phase 1 (0–12 months): Consolidate clinical credibility and operations

• Prioritize 6–8 flagship SKUs for clinical trials focused on pigmentation and texture endpoints in Indian cohorts.
• Expand the Centre of Excellence’s capabilities: analytical labs, clinical coordination team and data management systems.
• Strengthen manufacturing quality systems (GMP audits, stability monitoring) and secure alternative suppliers for key actives.
• Build a structured clinician engagement program with CME-type education, case reporting templates and co-branded patient education materials.

Phase 2 (12–24 months): Optimize D2C growth and product-market fit

• Invest in digital retention: subscription models for maintenance, adherence nudges, and tele-dermatology follow-ups.
• Run localized consumer studies in target international markets to test cosmetic acceptability (texture, finish, scent) and efficacy in those populations.
• Start regulatory mapping for one prioritized export market and align labeling and claims accordingly.

Phase 3 (24–36 months): International launch and scale

• Launch in 1–2 pilot markets (one in Latin America, one in East Asia) using local dermatologist partnerships and targeted D2C channels.
• Amplify medical affairs: publish clinical trial results in peer-reviewed journals or present at dermatology conferences to cement the brand’s scientific credentials.
• Explore selective retail partnerships—pharmacy or specialty beauty chains—where clinical positioning adds value.

Throughout these phases, maintain SKU discipline by retiring underperforming products and consolidating around high-margin, clinician-endorsed offerings.

Real-world parallels and lessons from other clinical-first brands

Several contemporary brands illustrate both the promise and pitfalls of clinic-led models.

• Brands that emerged from dermatology clinics and medical spas have shown rapid adoption when backed by clear clinical protocols and effective patient education. The advantage lies in pre-qualified patient cohorts and trust transference from clinician to product. However, many such brands struggle to translate clinic credibility into mass-market spreadsheets when they lack simplified regimens and consumer-facing education.
• Corporate venture participation by large incumbents often yields technical benefits: access to formulation platforms, toxicology expertise and global manufacturing networks. Yet corporate ties can also limit agility if integration expectations shift. Careful negotiation of strategic alignment versus operational independence is essential.
• D2C disruptors that scaled quickly through social media offer lessons in customer acquisition and community building. The key takeaway is not to mimic fast-fashion messaging, but to combine rigorous science with compelling storytelling that emphasizes outcomes and clinician endorsement.

CHOSEN appears to blend these elements: clinical foundations, investor-backed scale potential and a D2C channel that retains customer data and margin.

Risks to watch and mitigation strategies

No growth plan is risk-free. Four critical risks require continuous mitigation.

1. Clinical credibility erosion Risk: If products fail to deliver or adverse events for certain actives occur in sensitive skin, clinician trust will erode. Mitigation: Prioritize tolerability in formulations; institute robust adverse event monitoring and rapid response protocols; publish data transparently.
2. Channel conflict with clinics Risk: Aggressive D2C promotions could undermine clinic referrals. Mitigation: Maintain differentiated pricing and product assortments for clinic-prescribed regimens versus online maintenance lines; provide clinics with exclusive training and value-adds.
3. Regulatory traps in new markets Risk: Unexpected ingredient restrictions or claim limitations can delay launches. Mitigation: Engage local regulatory consultants early; prepare adaptable formulations and labeling; plan for staggered market entry.
4. Cost-of-goods and margin pressure Risk: High clinical validation costs plus premium manufacturing could compress margins. Mitigation: Prioritize R&D spend on high ROI products, negotiate supplier contracts, and explore scalable contract manufacturing partnerships.

The broader market implication: specialization and clinical trust as currency

CHOSEN’s trajectory exemplifies a broader shift in skincare. Consumers increasingly demand targeted solutions backed by clinical evidence, especially for persistent concerns like pigmentation and PIH. This demand elevates brands that can combine data from real-world practice with solid R&D and trustworthy clinician partnerships.

In markets where dermatologists hold prescribing power, clinic-to-consumer pathways are powerful distributors of trust. At the same time, direct-to-consumer channels remain essential for long-term margin management and customer lifetime value. Brands that successfully bridge these worlds will shape the next wave of global skincare players.

CHOSEN’s $5 million round does more than finance growth: it signals investor confidence in clinically oriented, skin-of-color-centered product strategies. Execution will determine whether clinical credibility translates into scale, profitability and meaningful global presence.

FAQ

Q: What exactly will CHOSEN use the $5 million Series A for? A: The company will invest in strengthening R&D capabilities, expanding its pipeline of clinically validated products, scaling its Centre of Excellence and hiring talent across functions. Operationally, these investments aim to accelerate clinical trials, fortify manufacturing quality, deepen clinician partnerships and enable targeted international expansion.

Q: How does CHOSEN’s clinic-to-consumer model work? A: CHOSEN collaborates with dermatologists and clinics that prescribe its products during treatment. Patients begin treatment under clinical supervision and then acquire maintenance products through CHOSEN’s D2C platform. This model leverages clinician credibility to drive initial adoption and D2C channels for retention and recurring revenue.

Q: Why is focusing on melanin-rich skin important? A: Melanin-rich skin presents specific dermatological needs—higher susceptibility to hyperpigmentation, distinct inflammation responses and particular aging patterns. Treatment regimens require actives and dosing strategies that minimize irritation and PIH risk while effectively addressing pigmentation and texture. Tailored formulations and clinician oversight reduce the risk of adverse outcomes.

Q: Who invested in this round and why does that matter? A: The round was led by Fireside Ventures, with participation from BOLD (L’Oréal’s corporate VC), Alkemi Growth Capital and angel investors including Avnish Anand and others. Fireside brings consumer brand scaling expertise; BOLD offers strategic advantages like technical know-how and potential pathways to global manufacturing and distribution. Such investors can accelerate product validation and market entry.

Q: What are the main product categories CHOSEN offers? A: CHOSEN’s portfolio includes topical formulations and nutraceuticals focused on pigmentation, texture, contour and hair aging. The brand currently lists around 58 SKUs across doctor-led and D2C segments.

Q: How big is CHOSEN’s clinician reach? A: Its products are prescribed in more than 2,000 clinics across India, and the company reports over 150,000 consultations informing its product design and clinical feedback.

Q: How reliant is CHOSEN on digital sales? A: About 95% of CHOSEN’s digital sales occur through its own platform, indicating a strong D2C orientation and control over customer relationships.

Q: What are the biggest challenges CHOSEN might face expanding internationally? A: Challenges include navigating varied regulatory regimes, adapting formulations and marketing to local cultural norms, building local clinician partnerships, managing supply chain and ingredient sourcing, and handling channel mix to preserve clinic relationships while scaling D2C.

Q: Which markets is CHOSEN targeting next? A: The company has signaled interest in “skin of color” markets in Latin America and East Asia—regions with significant demand for pigmentation and aging solutions appropriate for darker skin tones.

Q: How can CHOSEN maintain clinical credibility while growing fast? A: By prioritizing controlled clinical trials, maintaining transparency on outcomes and safety, building robust post-market surveillance, equipping clinicians with education, and ensuring product quality through validated manufacturing and stability protocols.

Q: What does a 70% repeat revenue figure tell us? A: High repeat revenue suggests product efficacy and strong customer loyalty. For clinically oriented brands, repeat purchases imply that patients see measurable results and are willing to continue maintenance regimens.

Q: How does CHOSEN compare to established brands like Cetaphil or Shiseido? A: Established brands offer distribution depth and recognized names; CHOSEN differentiates through focused science for melanin-rich skin, clinic-led validation and a combined topical-nutraceutical approach. Its niche specialization and clinician adoption create a value proposition that legacy brands may not match directly, though competition on scale and marketing is significant.

Q: What should clinicians expect if they partner with CHOSEN? A: Clinicians can expect access to dermatologist-focused protocols, clinical data, and a supply of products intended for practitioner-prescribed regimens. CHOSEN’s Centre of Excellence may support training and provide resources for monitoring outcomes.

Q: Are nutraceuticals effective for pigmentation and skin aging? A: Nutraceuticals can support skin health by providing systemic antioxidants, collagen-supporting peptides and micronutrients that complement topical interventions. However, efficacy varies by ingredient, formulation, dose and study quality—clinically validated products with randomized or controlled trials offer the most reliable evidence.

Q: How will CHOSEN balance price and clinical quality? A: Balancing affordability with clinical-grade formulations requires optimizing manufacturing costs, selective ingredient prioritization, and possibly tiered product lines—clinician-only prescription products versus maintenance-focused D2C offerings—so clinical lines maintain higher potency while consumer maintenance products emphasize tolerability and value.

Q: What signals would indicate CHOSEN is succeeding post-Series A? A: Indicators include successful completion and publication of clinical trials, increased clinic adoption and retention, improved unit economics on D2C channels (lower customer acquisition costs, higher LTV), successful pilot launches in target international markets, and operational milestones such as scaled manufacturing with consistent quality.

Q: What should consumers look for when choosing a product for melanin-rich skin? A: Seek clinically validated formulations, prioritize comprehensive photoprotection, choose gentle but effective actives (e.g., niacinamide, azelaic acid, tranexamic acid, stabilized vitamin C), watch for irritation potential, and consult dermatologists for high-efficacy protocols—especially when combining actives like retinoids and acids.

Q: Will CHOSEN likely seek additional funding later? A: Growth trajectories that include international expansion, large-scale clinical trials and manufacturing scale often require further capital. Future rounds could target larger strategic investors or partnerships that provide distribution and regulatory support.

Q: Where can clinicians and consumers find CHOSEN products? A: CHOSEN products are available via its D2C platform and prescribed in over 2,000 clinics across India. For international availability, consumers should await official brand announcements tied to local launches.

CHOSEN’s Series A reflects market appetite for clinically rigorous, skin-of-color-focused solutions. The next phase will test whether the brand can preserve clinical integrity while scaling operations, expanding internationally and converting prescriber trust into lasting consumer loyalty. Execution across R&D, manufacturing, clinician relations and localized market strategies will determine whether CHOSEN transitions from a promising Indian dermatology-led startup into a global reference for melanin-rich skin care.